Department of Internal Medicine, University of Pisa, Via Roma 67, 56100 Pisa, Italy.
J Endocrinol Invest. 2013 Apr;36(4):216-20. doi: 10.1007/BF03347275.
To investigate the systemic renin-angiotensin system (RAS) in essential hypertensives (EH) and controls (C) after short- and long-term vitamin D receptor activation.
Ten consecutive EH (under controlled low-salt diet) and 10 C underwent calcitriol administration (0.25 μg bid) for 1 week (Group A). Eighteen consecutive EH under angiotensin II receptor antagonist therapy received a single oral dose of 300,000 IU of cholecalciferol and were followed up for 8 weeks (Group B).
In basal conditions and at the end of the study (1 week in Group A and 8 weeks in Group B), plasma renin activity (PRA), plasma active renin, aldosterone, and angiotensin II were evaluated, as well as blood pressure, plasma 25-hydroxyvitamin D [25(OH)D], 1,25-dihydroxyvitamin D [1,25(OH)2D], and PTH.
In Group A, plasma 25(OH)D levels in EH and C were below the normal range, although lower levels were found in the former. No association between basal plasma 25(OH)D or 1,25(OH)2D levels and blood pressure values or RAS components was observed either in the whole group or in the two subgroups. Calcitriol administration did not affect any RAS parameter either in EH or in C. In Group B, cholecalciferol significantly increased 25(OH)D and 1,25(OH)2D levels without interfering with the angiotensin II receptor antagonist-induced increase in RAS components. No correlation was found between plasma 25(OH)D or 1,25(OH)2D levels and blood pressure values or RAS parameters before and after cholecalciferol administration.
The present data suggest that, in our experimental conditions, vitamin D receptor activation is unable to influence systemic RAS activity.
研究短期和长期维生素 D 受体激活后原发性高血压(EH)患者和对照组(C)的系统性肾素-血管紧张素系统(RAS)。
连续 10 例 EH(在低盐饮食控制下)和 10 例 C 接受了 1 周的钙三醇(0.25 μg bid)治疗(A 组)。18 例连续接受血管紧张素 II 受体拮抗剂治疗的 EH 患者单次口服 30 万 IU 胆钙化醇,并随访 8 周(B 组)。
在基础状态和研究结束时(A 组为 1 周,B 组为 8 周),评估血浆肾素活性(PRA)、活性肾素、醛固酮和血管紧张素 II,以及血压、血浆 25-羟维生素 D [25(OH)D]、1,25-二羟维生素 D [1,25(OH)2D]和甲状旁腺激素。
在 A 组中,EH 和 C 的血浆 25(OH)D 水平低于正常范围,尽管前者水平更低。在整个组或两个亚组中,基础血浆 25(OH)D 或 1,25(OH)2D 水平与血压值或 RAS 成分之间均无关联。钙三醇治疗对 EH 或 C 中的任何 RAS 参数均无影响。在 B 组中,胆钙化醇显著增加了 25(OH)D 和 1,25(OH)2D 水平,而不干扰血管紧张素 II 受体拮抗剂诱导的 RAS 成分增加。在胆钙化醇给药前后,血浆 25(OH)D 或 1,25(OH)2D 水平与血压值或 RAS 参数之间均无相关性。
本研究数据表明,在我们的实验条件下,维生素 D 受体激活不能影响系统性 RAS 活性。